GlassScriptPhysician profile
Diane Mladjen
NPI 1457991333
$3,636.00
in general payments reported to CMS, 2019-2025
30 companies · $716 in 2025
The $716 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.49 · 2022: $650 · 2023: $754 · 2024: $1,498 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524 · Travel and Lodging: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.08 |
| Travel and Lodging | $444.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,007.10 | 2023-2024 | Axonics |
| Janssen Biotech, INC. | $492.32 | 2022-2025 | Erleada, Carvykti, Rybrevant |
| Pfizer INC. | $273.04 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $194.02 | 2023-2025 | Gemtesa, Orgovyx |
| Acerus Pharmaceuticals Corporation | $159.66 | 2022 | |
| Urovant Sciences INC | $155.15 | 2021-2022 | |
| Boston Scientific Corporation | $142.35 | 2025 | Axonics |
| Medtronic, INC. | $127.00 | 2022-2024 | Interstim |
| Antares Pharma, INC. | $125.86 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Tolmar Pharmaceuticals, INC. | $102.72 | 2022 | |
| Astellas Pharma US INC | $99.92 | 2025 | Xtandi |
| Ferring Pharmaceuticals INC. | $93.24 | 2025 | Adstiladrin |
| Procept Biorobotics Corporation | $80.39 | 2025 | |
| Tolmar, INC. | $69.12 | 2023-2024 | |
| Coloplast Corp | $67.12 | 2023-2024 | Speedicath |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $64.17 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $51.12 | 2025 | |
| Progenics Pharmaceuticals, INC. | $40.55 | 2023 | Pylarify |
| Accord Healthcare, INC. | $38.64 | 2022-2024 | |
| Endo Pharmaceuticals INC. | $35.36 | 2023 | Xiaflex, Edex, Aveed |
| Immunitybio, INC. | $29.93 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.81 | 2023 | |
| Genzyme Corporation | $25.43 | 2022 | |
| Endo USA, INC. | $22.04 | 2025 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $21.05 | 2023 | Prolaris |
| Halozyme INC | $20.05 | 2023 | |
| Urogen Pharma, INC. | $19.36 | 2024 | |
| Abc Home Medical Supply, INC. | $19.00 | 2024 | |
| Olympus America INC. | $15.68 | 2023 | Itind System |
| Abbvie INC. | $14.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Mladjen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.